Healthcare >> CEO Interviews >> June 13, 2011
Christopher Anzalone, Ph.D. is the President and CEO of Arrowhead Research Corporation. He has a wealth of experience in nanotechnology, biotechnology, company building and venture capital. Prior to joining Arrowhead, Dr. Anzalone founded and built The Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Included in The Benet Group's portfolio are investments in two nanotechnology companies: Nanotope Inc., a tissue-regeneration company, and Leonardo Biosystems, Inc., a cancer drug-delivery company. Prior to Benet, Dr. Anzalone was a Partner at Galway Partners, LLC, a private equity firm based in Washington, D.C., where he was in charge of sourcing, structuring and building new business ventures. He was also the Founding CEO of NanoInk, Inc., a leading nanolithography company. Dr. Anzalone holds a Ph.D. and M.A. in biology from the University of California, Los Angeles, and a B.A. in government from Lawrence University. Profile
TWST: Would you begin with a brief historical sketch of the company?
Dr. Anzalone: We started as a diversified nanotechnology company. The idea was to build a holding company with multiple
